Literature DB >> 20660914

Visualisation of treatment response in a case of cerebrotendinous xanthomatosis.

Stefan Seidel, Gregor Kasprian, Daniela Prayer, Martin Krssák, Thomas Sycha, Eduard Auff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20660914     DOI： 10.1136/jnnp.2009.196444

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

Review 1.  Treatment of Smith-Lemli-Opitz syndrome and other sterol disorders.

Authors:  Melissa D Svoboda; Jill M Christie; Yasemen Eroglu; Kurt A Freeman; Robert D Steiner
Journal:  Am J Med Genet C Semin Med Genet       Date:  2012-10-05       Impact factor: 3.908

Review 2.  Natural history of neurological abnormalities in cerebrotendinous xanthomatosis.

Authors:  Janice C Wong; Kailey Walsh; Douglas Hayden; Florian S Eichler
Journal:  J Inherit Metab Dis       Date:  2018-02-26       Impact factor: 4.982

3.  Brain diffusion tensor imaging changes in cerebrotendinous xanthomatosis reversed with treatment.

Authors:  Claudia B Catarino; Christian Vollmar; Clemens Küpper; Klaus Seelos; Constanze Gallenmüller; Joanna Bartkiewicz; Saskia Biskup; Konstanze Hörtnagel; Thomas Klopstock
Journal:  J Neurol       Date:  2017-12-19       Impact factor: 4.849

Review 4.  Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

Authors:  Shuke Nie; Guiqin Chen; Xuebing Cao; Yunjian Zhang
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

5.  Cerebrotendinous Xanthomatosis: Molecular Pathogenesis, Clinical Spectrum, Diagnosis, and Disease-Modifying Treatments.

Authors:  Shingo Koyama; Yoshiki Sekijima; Masatsune Ogura; Mika Hori; Kota Matsuki; Takashi Miida; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-05-08       Impact factor: 4.928
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.